Bayer pharma loses momentumAlthough Bayer's pharmaceuticals business is still developing solidly overall, it has lost momentum in the first half of 2018 compared with previous years, Handelsblatt wrote on Tuesday (p26-27) in an analysis of Bayer's latest financial report.
Bayer share price falls againBayer's share price fell by around €70 on Tuesday for the first time since August 2013, reported FAZ (p23) and Handelsblatt (p36) on Wednesday.
Bayer forced to add safety warning on plant-based treatment IberogastGerman regulator BfArM has asked Bayer to include a warning about potential liver damage in the leaflet of its over-the-counter plant-based medicine Iberogast, one of the most popular gastrointestinal products in Germany, reported FAZ (p21) on Thursday.
German start-up works on software for pharma 'quantum computer'Start-up Heisenberg Quantum Simulations, a spinoff from the Karlsruhe institute of Technology, is developing software to create virtual drug trials on a new type of computer, Sueddeutsche Zeitung (SZ) (p28) reported on Thursday.
Legal action against hepatitis C drug patentNon-governmental organisations Doctors of the World and Doctors Without Borders are contesting the validity of Gilead's patent on sofosbuvir, the active ingredient of hepatitis C drug Sovaldi, Die Welt (p20) reported on Thursday.
Pharma-sponsored seminars under suspicionSeveral regional doctors' associations are currently reviewing pharma-sponsored seminars organised by OmniaMed after the Baden-Württemberg association refused certification to doctors attending one event, reported Handelsblatt (p22-23) on Monday.
Roche, BASF in Green party economic councilTwo top executives from German pharmaceuticals and chemicals firms, Roche Germany head Hagen Pfundner and BASF CEO Martin Brudermueller, will join the 50-member newly founded economic council of the German Green party, said Handelsblatt on Monday (p9).
Two new German research centres planned to promote translational medicineGerman research minister Anja Karliczek announced the setting up of two new centres for paediatric and psychiatric research to develop candidates for new drugs or other interventions and to market them in cooperation with pharma companies, SZ reported on Monday (p14).
Shortage of allergic emergency medicationPharmacies in Munich are waitlisting clients for adrenalin autoinjectors and cortisol drugs, SZ reported on Tuesday (p33).
Positive study results for Merck KgaA's BavencioMerck KGaA has announced positive results for its cancer immunotherapy therapy Bavencio (avelumab) in combination with Pfizer's Inlyta (axitinib) in renal cancer, FAZ reported on Wednesday (p19) (APMHE 59646).
Alcon moves HQ to GenevaBasel-based group Novartis intends to relocate the head office of its subsidiary Alcon to Geneva in 2019, FAZ reported on Wednesday (p19).
U.S. doctors 'partly to blame' for opioid crisisU.S. doctors are also to blame for the opioid crisis, according to a study on prescriptions from 2006 to 2015 in the U.S. published in the Annals of Internal Medicine, FAZ said on Thursday (p7).
New lawsuit against Purdue PharmaLast week, a complaint was filed against Purdue Pharma, manufacturer of opioid OxyContin (oxycodon), in the state of Colorado for "addictive drugs combined with ruthless marketing", SZ wrote on Wednesday (p4).
Nostrum Laboratories defends antibiotic price hike as 'moral duty'Nirmal Mulye, the CEO of Nostrum Laboratories, has defended his decision to raise the price of antibiotic nitrofurantoin - which has been used to treat bladder infections since 1953 - by 404% from $474.75 to $2,392, SZ wrote on Wednesday (p16) (APMHE 59656).
TRY APM HEALTH EUROPE AND GET ACCESS TO THE FULL CONTENT
Interviews with KOLs/senior executives amongst the Regulators, Payers, Health, Medical & Pharmaceutical organisations
Events coverage with a unique focus on Market Access & sustainability of healthcare systems
6 European bureaus : Berlin, Brussels, London, Madrid, Milan & Paris
Ask for a Free trial and get access to our last stories
- Health Care
- Market Access
- HTA – policies & practices
- European medicine regulations
- Drug safety issues
- Pricing & Reimbursement
- International medicines agencies
If you are a Payer, Pharmaceutical or Consulting professional our premium data will keep you informed on the regulatory, pricing, market access and cost-effectiveness issues that impact all stakeholders.
an initial 10 day temporary access of APM Health Europe.